$10.2M NIH grant awarded to study risk factors for malignant arrhythmias in mitral valve prolapse

Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse.

Pharmacovigilance in Crisis: Automation as the Answer to Workforce Shortages

Scott Fonseca, Sr. Director of Business Development at IQVIA The healthcare industry is no stranger to workforce shortages, and the pharmaceutical industry may be next

March 22, 2024

As bluebird projects more commercial demand, the biotech continues to seek cash

Bluebird bio reported that 17 people with sickle cell disease have started the process of receiving its gene therapy Lyfgenia. Bluebird said in its …

November 15, 2024

US approval for innovative immunoglobulin Yimmugo – Biotech Investments

EQS-News: Biotest AG / Key word(s): Regulatory Approval Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo 17.06.2024 / 09:00 CET/CEST The issuer is solely

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.